JNSS 2025, 16(1):55-56 | DOI: 10.32725/jnss.2025.002

Rivaroxaban - the clinical significance of plasma half-life in relation to age

Petr Petr1, 2, *, Josef ©véda3, Miroslav Verner2, 4, Hana Kalová1, Brigita Janečková1
1 České Budějovice Hospital, Clinical Pharmacology Ward, České Budějovice, Czech Republic
2 University of South Bohemia in České Budějovice, Faculty of Health and Social Sciences, České Budějovice, Czech Republic
3 Clinical / Hospital Pharmacy Ward, Central Pharmacy, České Budějovice Hospital, Czech Republic
4 České Budějovice Hospital, Central Laboratory Department, České Budějovice, Czech Republic

Received: March 6, 2025; Accepted: April 30, 2025; Prepublished online: May 2, 2025; Published: July 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petr P, ©véda J, Verner M, Kalová H, Janečková B. Rivaroxaban - the clinical significance of plasma half-life in relation to age. Journal of Nursing, Social Studies, Public Health and Rehabilitation. 2025;16(1-2):55-56. doi: 10.32725/jnss.2025.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Kubitza D, Becka M, Roth A, Mueck W (2008). Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24(10): 2757-2765. DOI: 10.1185/03007990802361499. Go to original source... Go to PubMed...
    2. . Mueck W, Stampfuss J, Kubitza D, Becka M (2014). Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clin Pharmacokinet 53: 1-16. DOI: 10.1007/s40262-013-0100-7. Go to original source... Go to PubMed...
    3. . State Institute for Drug Control (2023). Souhrn údajů o přípravku Xarelto, pp. 1-33.
    4. Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2005). Safety and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood 106(11): 1872. DOI: 10.1182/blood.V106.11.1872.1872. Go to original source...
    5. Stampfuss J, Kubitza D, Becka M, Mueck W (2013). The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharm Th 51(7): 549-561. DOI: 10.5414/CP201812. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content